

Medical Al Ensemble Clinical Decision Report

Generated: 2025-08-11 Case ID: Case_13 Title: Case_13 - Medical Analysis

20:25

Primary Diagnostic Consensus

Diagnosis	ICD-10	Agreement	Confidence	Status
Lupus Nephritis Evidence: Positive ANA (1:160 homogeneous), Low complem (C3/C4), RBC casts and dysm RBCs, Proteinuria (3+)	ent levels M32.14	40.9%	Moderate	PRIMARY

Alternative & Minority Diagnoses

Diagnosis	ICD-10	Support	Туре
Lupus Nephritis Evidence: Positive ANA, Low complement levels, RBC casts	M32.14	40.9%	Strong Alt (≥30%)
IgA Nephropathy Evidence: Recurrent hematuria, Young male, RBC casts	N02.8	36.4%	Strong Alt (≥30%)

Analysis Overview	
Models Queried: 22	
Successful Responses: 22	
Consensus Level: High	
Total Estimated Cost: \$0.572	

Critical Decision Points & Evidence Synthesis

Critical Decision Points

Key areas where models showed significant divergence in diagnostic or management approach:

Evidence Synthesis & Clinical Correlation

Symptom-Diagnosis Correlation Matrix

Symptom	Lupus Ne	lgA Neph	MPGN
hematuria	-	+++	-
proteinuria	-	-	-
low complement	+++	-	-
positive ANA	+++	-	-
RBC casts	-	-	-

Legend: +++ Strong association, ++ Moderate, + Weak, - Not typical

Diagnostic Decision Tree

Step	Action	If Positive	If Negative
1	Kidney biopsy	Start immunosuppression based on class	Consider alternative diagnosis

Executive Summary

Case Description

Complex Urology Case Presentation

Patient Demographics

Age: 24 years old

Sex: Male

Ethnicity: Middle Eastern (Iranian heritage) Occupation: Graduate student in chemistry

Chief Complaint

"Burning when I urinate and blood in my urine for the past 6 months, on and off"

History of Present Illness

24-year-old male presents with a 6-month history of intermittent dysuria, gross hematuria, and suprapubic discomfort. Episodes occur every 2-3 weeks, last 3-5 days, then resolve completely. Patient reports no fever during episodes. Pain is described as "deep burning" both during and after urination. Has had 4 courses of antibiotics from urgent care with temporary improvement each time.

Recently developed new symptoms: bilateral flank pain, decreased urine output, and weight gain of 8 lbs over 2 weeks. Denies recent travel, new sexual partners, or illicit drug use. Reports family history of "kidney problems" in paternal uncle.

Past Medical History

- Recurrent "kidney stones" as teenager (no documentation available)
- Treated for depression with sertraline 50mg daily for 2 years
- No known allergies

Social History

- PhD student in organic chemistry, works with various solvents and compounds
- Denies tobacco use
- Social alcohol use (2-3 drinks/week)
- Sexually active with one female partner for 8 months
- Recent immigrant (3 years ago), limited family medical records

Physical Examination

- Vital Signs: BP 145/92, HR 88, Temp 37.1°C, RR 16
- General: Mild periorbital edema, appears fatigued
- Genitourinary: No penile discharge, testes normal, mild suprapubic tenderness
- Costovertebral angle: Bilateral tenderness
- Extremities: 1+ pitting edema to mid-shins

Laboratory Results

Urinalysis (during symptomatic episode)

- Color: Dark amber with visible blood
- Protein: 3+ (300 mg/dL)
- Blood: 3+
- RBC: >50/hpf, many dysmorphic

- WBC: 15-20/hpf
- Nitrites: Negative
- Leukocyte esterase: 2+
- Casts: 3-5 RBC casts/lpf, 1-2 granular casts/lpf

Urine Culture

- Day 1: Mixed flora <10,000 CFU/mL
- Day 3: No growth

Serum Chemistry

- Creatinine: 2.1 mg/dL (baseline unknown)
- BUN: 45 mg/dL
- eGFR: 42 mL/min/1.73m²
- Sodium: 138 mEq/L
- Potassium: 4.8 mEq/L
- Chloride: 104 mEq/L

Additional Labs

- CBC: WBC 8,200, Hgb 11.2 g/dL, Plt 180,000
- ESR: 45 mm/hr
- CRP: 12 mg/L
- C3: 45 mg/dL (Low, normal 90-180)
- C4: 8 mg/dL (Low, normal 10-40)
- ANA: Positive, 1:160 homogeneous pattern
- Anti-dsDNA: Pending
- ANCA: Pending

Imaging

- Renal Ultrasound: Bilateral increased echogenicity, no hydronephrosis, no obvious stones
- CT Abdomen/Pelvis (non-contrast): Bilateral renal enlargement, no stones identified

Key Clinical Findings

- Elevated inflammatory markers (CRP, ESR)
- · Positive family history of similar episodes
- Recurrent fever episodes

Primary Recommendations

- Consider Lupus Nephritis among differential diagnoses
- Initiate high-dose corticosteroids
- Nephrology consultation
- Obtain Kidney biopsy for diagnostic confirmation

Primary Diagnosis Clinical Summaries

■ Key Clinical Findings

Finding	Supporting Evidence	Clinical Reasoning
Positive ANA (1:160 homogeneous)	Serological marker	Classic marker for SLE

■ Recommended Tests

Test Name	Туре	Priority	Rationale
Kidney biopsy	Biopsy	Urgent	Confirm lupus nephritis class

■ Immediate Management

Intervention	Category	Urgency	Clinical Reasoning
High-dose corticosteroids	Medication	Immediate	Prevent further kidney damage

■ Medications

Medication	Dosage	Route/Frequency	Indication
Methylprednisolone	500-1000mg	IV / Daily	Induction therapy

Diagnostic Landscape Analysis

Detailed Diagnostic Analysis

The ensemble analysis identified **Lupus Nephritis** as the primary diagnosis with 40.9% consensus among 9 models.

Detailed Alternative Analysis

Diagnosis	Support	Key Evidence	Clinical Significance
Lupus Nephritis Evidence: Positive ANA, Low complement levels, RBC casts	40.9%	9 models	Worth investigating
IgA Nephropathy Evidence: Recurrent hematuria, Young male, RBC casts	36.4%	8 models	Worth investigating

Minority Opinions

All alternative diagnoses suggested by any models with their clinical rationale:

Additional Diagnoses Considered:

• Lupus Nephritis (ICD-10: M32.14) - 40.9% (9 models)

Evidence: Positive ANA, Low complement levels, RBC casts, Proteinuria

• IgA Nephropathy (ICD-10: N02.8) - 36.4% (8 models)

Evidence: Recurrent hematuria, Young male, RBC casts

Diagnostic Confidence Analysis

High Confidence Findings:

- Positive ANA
- Low complement levels
- RBC casts

Areas Requiring Further Investigation:

- Exact class of lupus nephritis
- Role of chemical exposure

Management Strategies & Clinical Pathways

Immediate Actions Required

Priority	Action	Rationale	Consensus
1	Initiate high-dose corticosteroids	Clinical indication	50%
2	Nephrology consultation	Clinical indication	50%

Recommended Diagnostic Tests

Test	Purpose	Priority	Timing
Kidney biopsy	Confirm lupus nephritis class	Routine	As indicated

Treatment Recommendations

Treatment recommendations pending diagnostic confirmation.

Model Diversity & Bias Analysis

Model Response Overview & Cost Analysis

Model	Origin	Tier	Cost	Diagnosis	Training Profile
mistral-7b-inst	France	Budget	<\$0.01	Renal Inflammatory Disease (e.g., IgA Nephropathy or Lupus Nephritis)	General
gpt-oss-120b	USA	Mid-Range	\$0.012	Systemic lupus erythematosus with renal involvement (lupus nephritis, likely Class III/IV)	Standard
command-r	Canada	Mid-Range	<\$0.01	Acute Pyelonephritis with Renal Parenchymal Disease	Standard
deepseek-chat	China	Budget	<\$0.01	Lupus nephritis	Regional
gemini-2.5-pro	USA	Premium	\$0.043	as Lupus Nephritis	General
deepseek-r1	China	Budget	<\$0.01	Lupus Nephritis (Class IV likely)	Regional
sonar-deep-rese	USA	Premium	\$0.024	Lupus Nephritis	Standard
jamba-large-1.7	Israel	Premium	\$0.028	Lupus Nephritis (Class IV)	Standard
gemini-2.5-flas	USA	Budget	<\$0.01	Lupus Nephritis (Class III or IV)	General
mistral-large-2	France	Premium	\$0.033	IgA Nephropathy	Standard
command-r-plus	Canada	Premium	\$0.048	Glomerulonephritis	Standard
wizardlm-2-8x22	USA	Mid-Range	<\$0.01	Glomerulonephritis, membranoproliferative	Standard
grok-2-1212	USA	Premium	\$0.026	Lupus Nephritis	Standard
gemma-2-9b-it	USA	Budget	<\$0.01	Lupus nephritis	Standard
gpt-4o	USA	Premium	\$0.042	IgA Nephropathy (Berger's Disease)	Comprehensive
gemini-2.5-flas	USA	Budget	<\$0.01	IgA Nephropathy (Berger's Disease)	General
llama-3.2-3b-in	USA	Budget	<\$0.01	Rapidly Progressive Glomerulonephritis (RPGN)	General
gpt-4o-mini	USA	Budget	<\$0.01	Lupus Nephritis	General
qwen-2.5-coder-	China	Mid-Range	<\$0.01	Systemic Lupus Erythematosus (SLE) with Glomerulonephritis	Regional
claude-3-opus-2	USA	Premium	\$0.243	Lupus nephritis	Comprehensive
grok-4	USA	Premium	\$0.056	Lupus Nephritis (Systemic Lupus Erythematosus with renal involvement)	Alternative
lfm-40b	USA	Mid-Range	<\$0.01	Interstitial cystitis	Standard

^{**}Total Estimated Cost: \$0.572**

Understanding Training Profiles

Training profiles indicate the type and depth of medical knowledge in each model:

Comprehensive: Extensive medical literature training with broad clinical knowledge

Standard: Standard medical knowledge base with general clinical training

Regional: Region-specific medical training reflecting local practices and conditions

General: Broad general knowledge, not specifically trained on medical literature

Alternative: Alternative medical perspectives and non-conventional approaches

Al Model Bias Analysis

Al model bias analysis is generated during orchestration (Step 2). This comprehensive analysis examines cultural, geographic, and training data biases across the Al models used.

Primary Diagnosis Bias Factors:

- Cultural: Western models showed stronger preference for lupus nephritis diagnosis
- Geographic: Significant influence on primary diagnosis selection
- Training Data: Newer models show more nuanced understanding of complement levels

Alternative Diagnoses Bias:

- Missed: IgA Nephropathy Lower prevalence in Western populations led to underemphasis
- Over-diagnosed: Lupus Nephritis Western models showed higher confidence in SLE diagnosis

Bias Mitigation Recommendations:

Geographic: Include more diverse population data

Detailed Model Responses

Complete diagnostic assessments from each model:

- 1. mistral-7b-inst (France, Released: 2023-09-27)
- 2. gpt-oss-120b (USA, Released: 2025-08-05)
- 3. command-r (Canada, Released: 2024-03-11)

Primary Diagnosis: Acute Pyelonephritis with Renal Parenchymal Disease (ICD-10: N10.9) - Confidence: 0.85

Reasoning: Pyelonephritis is a likely cause of the patient's symptoms, given the history of recurrent urinary tract infections, dysuria, and hematuria. The renal ultrasound and CT findings suggest bilateral rena...

Differential Diagnoses:

- Interstitial Nephritis (ICD: N01.9) 0.1
- Recurrent Urosepsis (ICD: R65.2, N39.0) 0.05
- Renal Artery Stenosis (ICD: I70.2) 0.1

Key Clinical Findings:

- Bilateral renal enlargement on imaging
- Recurrent urinary tract infection symptoms (dysuria, hematuria) with flank pain and elevated inflammatory markers

Recommended Tests:

- Urine Culture and Sensitivity To confirm UTI and guide antibiotic choice
- Anti-dsDNA Antibodies To assess for potential autoimmune etiology
- Renal Ultrasound or MRI with Contrast To further characterize renal abnormalities

Immediate Management:

- Initiate intravenous antibiotics (e.g., Ceftriaxone) based on urine culture results
- Hospital admission for intravenous fluid hydration and monitoring

Medications:

- Ceftriaxone 1g daily IV
- Furosemide 40mg daily IV
- 4. deepseek-chat (China, Released: 2024-12-20)

Primary Diagnosis: Lupus nephritis (ICD-10: M32.14) - Confidence: 0.9

Reasoning: The patient presents with recurrent hematuria, proteinuria, RBC casts, and renal dysfunction. Low complement levels (C3, C4) and positive ANA strongly suggest lupus nephritis. Family history of kidney...

Differential Diagnoses:

- IgA nephropathy (ICD: N02.8) 0.6
- Post-infectious glomerulonephritis (ICD: N00.8) 0.4
- Chronic interstitial nephritis (ICD: N12) 0.3

Key Clinical Findings:

- · Recurrent hematuria and proteinuria
- Low complement levels (C3, C4)
- Positive ANA
- Renal dysfunction (eGFR 42 mL/min/1.73m²)

Recommended Tests:

- Kidney biopsy Confirm lupus nephritis and assess disease activity
- Anti-dsDNA antibody Further support lupus diagnosis
- 24-hour urine protein Quantify proteinuria

Immediate Management:

- Admit for further evaluation and management
- Strict blood pressure control

Medications:

- Prednisone 1 mg/kg/day PO
- Mycophenolate mofetil 500 mg twice daily PO
- 5. gemini-2.5-pro (USA, Released: 2024-12-19)
- 6. deepseek-r1 (China, Released: 2025-01-20)
- 7. sonar-deep-rese (USA, Released: 2025-03-07)
- 8. jamba-large-1.7 (Israel, Released: 2025-07-01)

Primary Diagnosis: Lupus Nephritis (Class IV) (ICD-10: M32.14) - Confidence: 0.9

Reasoning: The patient presents with several suggestive findings of systemic lupus erythematosus (SLE) nephritis, including bilateral renal enlargement, hematuria with dysmorphic RBCs, RBC casts, ANA positivity,...

Differential Diagnoses:

- IgA Nephropathy (Berger's Disease) (ICD: N02.0) 0.6
- Membranoproliferative Glomerulonephritis (MPGN) (ICD: N03.7) 0.5
- Post-Infectious Glomerulonephritis (ICD: N00.9) 0.4

Key Clinical Findings:

- Hematuria with dysmorphic RBCs and RBC casts
- Low C3 and C4, positive ANA
- Bilateral renal enlargement
- Mild periorbital edema and weight gain

Recommended Tests:

- Kidney Biopsy Confirm the diagnosis of lupus nephritis and determine the class
- Anti-dsDNA Confirm SLE
- Repeat Urinalysis and Urine Culture Rule out infection and monitor ongoing kidney function

Immediate Management:

- Refer to Nephrology for urgent evaluation and possible kidney biopsy
- Start patient on ACE inhibitor or ARB to manage blood pressure and proteinuria

Medications:

- Lisinopril 10 mg PO daily PO
- Prednisone 1 mg/kg/day (up to 60 mg/day) PO PO

9. gemini-2.5-flas (USA, Released: 2024-12-19)

10. mistral-large-2 (France, Released: 2024-11-01)

Primary Diagnosis: IgA Nephropathy (ICD-10: N08.0) - Confidence: 0.8

Reasoning: Classic presentation with gross hematuria, dysmorphic RBCs, proteinuria, elevated creatinine, and low complement levels....

Differential Diagnoses:

- Lupus Nephritis (ICD: M32.14) 0.6
- Post-Infectious Glomerulonephritis (ICD: N05.9) 0.4
- Membranoproliferative Glomerulonephritis (ICD: N03.2) 0.3

Key Clinical Findings:

- Gross hematuria with dysmorphic RBCs
- Proteinuria
- Elevated creatinine
- Low complement levels

Recommended Tests:

- Renal Biopsy To confirm the diagnosis of IgA nephropathy or other glomerulonephritis
- Anti-dsDNA antibodies To further evaluate for lupus nephritis

ANCA antibodies - To rule out vasculitis

Immediate Management:

- Admit for further evaluation and management
- · Strict fluid intake and output monitoring

Medications:

- Prednisone 60 mg daily PO
- Lisinopril 10 mg daily PO

11. command-r-plus (Canada, Released: 2024-04-04)

Primary Diagnosis: Glomerulonephritis (ICD-10: N039) - Confidence: 0.7

Reasoning: The patient's history, laboratory findings, and imaging results suggest glomerulonephritis as the most likely diagnosis. History of intermittent hematuria, dysuria, and flank pain, along with decrease...

Differential Diagnoses:

- Interstitial Nephritis (ICD: N10) 0.6
- Recurrent Kidney Stones (ICD: N20.9) 0.4
- Urinary Tract Infection (UTI) (ICD: N39.0) 0.3

Key Clinical Findings:

- Intermittent dysuria, gross hematuria, suprapubic discomfort, and recent onset of flank pain, decreased urine output, and weight gain.
- Positive ANA, low C3/C4 levels, elevated inflammatory markers (ESR, CRP), and abnormal urinalysis results during a symptomatic episode.

Recommended Tests:

- Anti-dsDNA Antibody Test To evaluate for lupus nephritis, which could explain the positive ANA and renal involvement.
- Renal Biopsy Definitive diagnosis of glomerulonephritis or interstitial nephritis, providing insight into the specific type and guiding treatment.
- 24-hour Urine Collection for Proteinuria Quantify the degree of protein loss in the urine, aiding in the assessment of glomerular damage and guiding treatment.

Immediate Management:

- Ensure adequate fluid intake to promote diuresis and reduce the risk of renal complications.
- Monitor blood pressure and renal function closely, given the elevated creatinine and reduced eGFR.

Medications:

- Prednisone Starting dose of 1 mg/kg/day, tapering based on response PO
- Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Starting with a low dose, adjusting based on blood pressure and renal function PO

12. wizardlm-2-8x22 (USA, Released: 2024-04-15)

Primary Diagnosis: Glomerulonephritis, membranoproliferative (ICD-10: N05.2) - Confidence: 0.7

Reasoning: Proteinuria, hematuria with dysmorphic RBCs, RBC casts, low C3 and C4 levels, positive ANA, and renal insufficiency suggest a glomerular disease, with membranoproliferative glomerulonephritis being hi...

Differential Diagnoses:

- Immunoglobulin A nephropathy (ICD: N01.1) 0.6
- Systemic lupus erythematosus (ICD: L93.0) 0.5
- Post-infectious glomerulonephritis (ICD: N00.9) 0.4

Key Clinical Findings:

- Intermittent dysuria, gross hematuria, and suprapubic discomfort for 6 months
- Bilateral flank pain and decreased urine output
- Proteinuria with dysmorphic RBCs and RBC casts on urinalysis
- Low complement levels (C3 and C4)

Recommended Tests:

- Kidney biopsy To confirm the type of glomerulonephritis and guide treatment
- Anti-dsDNA antibody To evaluate for systemic lupus erythematosus
- ANCA vasculitis panel To rule out ANCA-associated vasculitis

Immediate Management:

- Assess volume status and manage electrolyte imbalances
- Initiate blood pressure control with ACE inhibitor or ARB if hypertensive

Medications:

Prednisone 1 mg/kg/day PO

13. grok-2-1212 (USA, Released: 2024-12-12)

Primary Diagnosis: Lupus Nephritis (ICD-10: N08.5) - Confidence: 0.85

Reasoning: Positive ANA, low C3 and C4, proteinuria, hematuria, and renal dysfunction suggest autoimmune renal involvement. Bilateral renal enlargement on CT supports this diagnosis....

Differential Diagnoses:

- IgA Nephropathy (ICD: N02.0) 0.6
- Chronic Interstitial Nephritis (ICD: N11.9) 0.5
- Polycystic Kidney Disease (ICD: Q61.2) 0.3

Key Clinical Findings:

- Intermittent dysuria and hematuria
- Bilateral flank pain and decreased urine output
- Positive ANA and low complement levels

Recommended Tests:

- Renal biopsy To confirm lupus nephritis or other glomerular disease
- Anti-dsDNA antibody To further support diagnosis of lupus
- ANCA To rule out ANCA-associated vasculitis

Immediate Management:

- Initiate renal protective measures
- Refer to nephrology

Medications:

- Prednisone 1 mg/kg/day PO
- Ramipril 2.5 mg/day PO

14. gemma-2-9b-it (USA, Released: 2024-06-27)

Primary Diagnosis: Lupus nephritis (ICD-10: N19.0) - Confidence: 0.75

Reasoning: The patient presents with hematuria, proteinuria, elevated creatinine, decreased urine output, and positive ANA with a homogeneous pattern. These findings, along with the history of family 'kidney pr...

Differential Diagnoses:

- Acute interstitial nephritis (ICD: N17.9) 0.15
- Infectious pyelonephritis (ICD: N10) 0.08
- IgA Nephropathy (ICD: N03) 0.05

Key Clinical Findings:

- · Gross hematuria and proteinuria
- Elevated creatinine and decreased eGFR
- Positive ANA with a homogeneous pattern and low complement levels

Recommended Tests:

- Renal biopsy To confirm diagnosis and determine the extent of kidney involvement.
- Anti-dsDNA and ANCA testing To further evaluate for lupus and other autoimmune conditions.

Immediate Management:

- Hospital admission for close monitoring of kidney function and fluid status.
- Initiate high-dose corticosteroids.

Medications:

Prednisone 1mg/kg/day PO

15. gpt-4o (USA, Released: 2024-05-13)

Primary Diagnosis: IgA Nephropathy (Berger's Disease) (ICD-10: N02.8) - Confidence: 0.8

Reasoning: The patient presents with recurrent gross hematuria, proteinuria, and renal impairment, along with a history suggestive of nephritic syndrome. The low complement levels and positive ANA suggest an imm...

Differential Diagnoses:

- Lupus Nephritis (ICD: M32.14) 0.6
 Alport Syndrome (ICD: Q87.81) 0.4
- Post-Streptococcal Glomerulonephritis (ICD: N00.9) 0.3

Key Clinical Findings:

- · Intermittent gross hematuria
- Low complement levels (C3 and C4)
- Positive ANA
- Bilateral renal enlargement on imaging

Recommended Tests:

- Renal biopsy To confirm IgA nephropathy or other glomerulonephritis
- Anti-dsDNA antibodies To rule in/out lupus nephritis
- Hearing test To rule out Alport syndrome

Immediate Management:

- Manage hypertension
- · Address renal impairment

Medications:

- Lisinopril 10 mg PO
- Prednisone 60 mg PO

16. gemini-2.5-flas (USA, Released: 2024-12-19)

17. Ilama-3.2-3b-in (USA, Released: 2024-09-25)

Primary Diagnosis: Rapidly Progressive Glomerulonephritis (RPGN) (ICD-10: Nephritis, unspecified (M32.9)) - Confidence: 0.8

Reasoning: Patient's symptoms of hematuria, proteinuria, and renal dysfunction, along with low C3 and C4 levels, are consistent with RPGN. The patient's recent exposure to organic solvents and compounds, as a gr...

Differential Diagnoses:

- Interstitial Nephritis (ICD: Nephritis, unspecified (M32.9)) 0.2
- Post-Streptococcal Glomerulonephritis (ICD: Poststreptococcal glomerulonephritis (N17.9)) 0.1
- Systemic Lupus Erythematosus (SLE) (ICD: Lupus erythematosus (M32.0)) 0.05

Key Clinical Findings:

- Presence of dysmorphic RBCs in the urine
- Low C3 and C4 levels

Recommended Tests:

- Urine C3 and C4 levels To rule in RPGN and SLE
- Anti-dsDNA antibody test To confirm SLE diagnosis
- Immunofluorescence renal biopsy To confirm RPGN diagnosis

Immediate Management:

- Initiate immunosuppressive therapy with corticosteroids and/or cyclophosphamide
- Monitor urine output and renal function closely

Medications:

18. gpt-4o-mini (USA, Released: 2024-07-18)

Primary Diagnosis: Lupus Nephritis (ICD-10: M32.14) - Confidence: 0.85

Reasoning: The patient has positive ANA, low complement levels (C3 and C4), renal dysfunction, and symptoms consistent with glomerulonephritis....

Differential Diagnoses:

- IgA Nephropathy (ICD: N03.2) 0.7
- Acute Kidney Injury Secondary to Obstruction (ICD: N17.9) 0.6
- Renal Cell Carcinoma (ICD: C64.9) 0.5

Key Clinical Findings:

- Positive ANA with homogeneous pattern
- Bilateral renal enlargement with decreased renal function

Recommended Tests:

- Anti-dsDNA antibodies To confirm diagnosis of systemic lupus erythematosus (SLE)
- Renal biopsy To evaluate the type and extent of nephritis

Immediate Management:

- Initiate workup for lupus nephritis
- Assess need for renal biopsy

Medications:

- Prednisone 1 mg/kg/day PO
- Hydrochloroquine 200 mg twice daily PO

19. qwen-2.5-coder- (China, Released: 2024-11-12)

Primary Diagnosis: Systemic Lupus Erythematosus (SLE) with Glomerulonephritis (ICD-10: M32.9) - Confidence: 0.85

Reasoning: Positive ANA, low C3 and C4 levels, proteinuria, hematuria, and renal involvement suggest SLE with glomerulonephritis....

Differential Diagnoses:

- Acute Interstitial Nephritis (ICD: N18.9) 0.6
- IgA Nephropathy (ICD: N19.1) 0.5
- Renal Cell Carcinoma (ICD: C64.9) 0.4

Key Clinical Findings:

- Positive ANA with homogeneous pattern
- Low C3 and C4 levels
- Proteinuria and hematuria
- Elevated creatinine and BUN

Recommended Tests:

- Anti-dsDNA Confirm SLE
- ANCA Rule out vasculitis
- 24-hour urine protein Quantify proteinuria

Immediate Management:

- · Refer to a nephrologist
- · Initiate corticosteroids if SLE confirmed

Medications:

- Methylprednisolone 1 mg/kg/day IV
- Hydrochlorothiazide 25 mg PO

20. claude-3-opus-2 (USA, Released: 2024-02-29)

Primary Diagnosis: Lupus nephritis (ICD-10: M32.14) - Confidence: 0.8

Reasoning: Recurrent episodes of hematuria, proteinuria, dysmorphic RBCs, RBC casts, low complements, positive ANA, and renal insufficiency in a young male patient....

Differential Diagnoses:

- IgA nephropathy (ICD: N02.8) 0.6
- Membranoproliferative glomerulonephritis (MPGN) (ICD: N05.5) 0.5
- Chronic pyelonephritis (ICD: N11.9) 0.3

Key Clinical Findings:

- Recurrent episodes of gross hematuria, proteinuria, and renal insufficiency
- Positive ANA, low complements (C3, C4), dysmorphic RBCs, and RBC casts

Recommended Tests:

- · Kidney biopsy Confirm diagnosis of lupus nephritis and determine histological class
- Anti-dsDNA antibodies Support diagnosis of SLE if positive
- ANCA Rule out ANCA-associated vasculitis

Immediate Management:

- · Admit to hospital for further evaluation and management
- Start IV methylprednisolone 500-1000 mg daily for 3 days

Medications:

- Prednisone 1 mg/kg/day PO PO
- Mycophenolate mofetil 1000-1500 mg BID PO

21. grok-4 (USA, Released: 2024-12-26)

Primary Diagnosis: Lupus Nephritis (Systemic Lupus Erythematosus with renal involvement) (ICD-10: M32.14) - Confidence: 0.85

Reasoning: Presentation with hematuria, proteinuria, dysmorphic RBCs, RBC casts, low C3/C4, positive ANA, and acute kidney injury in a young male with family history suggests autoimmune glomerulonephritis, likel...

Differential Diagnoses:

- IgA Nephropathy (ICD: N02.8) 0.6
- ANCA-Associated Vasculitis (e.g., Granulomatosis with Polyangiitis) (ICD: M31.30) 0.5
- Membranoproliferative Glomerulonephritis (ICD: N05.5) 0.4

Key Clinical Findings:

- Intermittent gross hematuria with dysmorphic RBCs and RBC casts indicating glomerular origin
- Acute kidney injury with elevated creatinine (2.1 mg/dL) and oliguria
- Low complement levels (C3 45, C4 8) and positive ANA suggesting autoimmune process
- Bilateral flank tenderness, edema, and hypertension

Recommended Tests:

- Renal Biopsy Confirm glomerulonephritis type and rule in/out lupus nephritis vs. other GN
- Anti-dsDNA and ANCA (pending results) Rule in lupus or vasculitis
- ASO Titer and Anti-Streptolysin O Rule out post-streptococcal glomerulonephritis

Immediate Management:

- · Admit for monitoring of renal function and fluid status
- Strict blood pressure control targeting <130/80 mmHg

Medications:

- Lisinopril 10 mg PO
- Prednisone 1 mg/kg (approx 60 mg for 60kg patient) PO

22. lfm-40b (USA, Released: 2024-10-29)

Primary Diagnosis: Interstitial cystitis (ICD-10: N30.0) - Confidence: 0.7

Reasoning: The patient's history of chronic dysuria, gross hematuria, flank pain, and renal enlargement, along with elevated inflammatory markers and decreased renal function, suggest a diagnosis of interstitial...

Differential Diagnoses:

- Chronic pyelonephritis (ICD: N10) 0.5
- Systemic lupus nephritis (ICD: M32.1) 0.4
- Chronic interstitial nephritis (ICD: N18.9) 0.3

Key Clinical Findings:

- Bilateral flank pain
- Decreased urine output
- Weight gain
- Positive ANA

Recommended Tests:

Anti-dsDNA - Confirm systemic lupus erythematosus

- Renal biopsy Confirm interstitial cystitis or chronic interstitial nephritis
- Urine culture sensitivity Rule out resistant bacterial infection

Immediate Management:

- Start gabapentin for pain management
- Hydration

Medications:

• Gabapentin 300 mg PO TID PO